On July 18, 2025, analyst Tazeen Ahmad from B of A Securities issued an updated evaluation for Sarepta Therapeutics (SRPT, Financial). The financial institution has maintained its "Neutral" rating for the biotech company, suggesting a steady sentiment regarding the stock's current performance.
In terms of price targets, B of A Securities has lowered its projection for Sarepta Therapeutics (SRPT, Financial). The new price target is set at USD 20.00, a significant decrease from the previous target of USD 28.00. This adjustment represents a decline of 28.57% in the expected share price.
The decision to lower the price target while maintaining the rating indicates a reassessment of the company’s valuation amidst current market conditions. Investors are advised to consider this revised target while evaluating their positions in Sarepta Therapeutics (SRPT, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $47.96 with a high estimate of $185.00 and a low estimate of $10.00. The average target implies an upside of 157.00% from the current price of $18.66. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $216.81, suggesting a upside of 1061.9% from the current price of $18.66. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
